APSA-ASCEPT-poster-abstracts-51217
➤ Gửi thông báo lỗi ⚠️ Báo cáo tài liệu vi phạmNội dung chi tiết: APSA-ASCEPT-poster-abstracts-51217
APSA-ASCEPT-poster-abstracts-51217
APSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 honen1, Laura Fanning1, Atte Meretoja2, Kevin p Me Namara3, Janet K Sluggett1, J Simon Bell1. Centre for Medicine Use and Safety, Monash Univ1, Parkville, VIC, Helsinki Univ Hosp, Head and Neck Center2, Helsinki, ^School of Medicine, Deakin Univ3, Warrnambool, VICIntroduction. People with dementia a APSA-ASCEPT-poster-abstracts-51217 re less likely to use anticoagulants for the prevention of thromboembolic events due to perceived increased bleeding risk. It is unclear to what extenAPSA-ASCEPT-poster-abstracts-51217
t the introduction of the direct oral anticoagulants (DOACs) has impacted the overall prevalence of anticoagulant use. Aims. To investigate the trendsAPSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 l Benefits Scheme individual-level dispensing data. People with dementia were identified as recipients of acetylcholinesterase inhibitors or memantine and categorised according to age 65-74 years, 75-84 years and >85 years.Results. The annual number of people with dementia increased from 5,709 in 20 APSA-ASCEPT-poster-abstracts-51217 09 to 8.937 in 2016. The overall prevalence of warfarin use increased from 3.6% to 4.7% and DOAC use from 0.04% to 7.0%. The pattern of anticoagulantAPSA-ASCEPT-poster-abstracts-51217
use was similar in sensitivity analyses excluding under copayment medications or restricting the cohort to concession card holders. Age-specific trendAPSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 ly since the introduction of DOACs. This may mean more people with dementia receive appropriate treatment. However, there is a need for further research in the benefits and risks of anticoagulant use in people With dementia.401Mapping medication burden, prescribing and dispensing patterns within com APSA-ASCEPT-poster-abstracts-51217 munity dwelling elderly clients of community pharmaciesLauren J Corre1, Elizabeth Hotham1, Vijayaprakash Suppiah1 School of Pharmacy and Medical ScienAPSA-ASCEPT-poster-abstracts-51217
ces, University of South Australia1, Adelaide, SA, Australia.Introduction. The coexistence of multiple illnesses in the elderly is common, and may leaAPSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 tive consequences. Currently, there is a lack of knowledge surrounding the needs of older Australians residing independently within the community.Aims. To quantify and describe: 1) Current patterns of medication load and presence of polypharmacy and, in particular, prevalence and variety of analgesi APSA-ASCEPT-poster-abstracts-51217 cs and any reported adverse events. 2) Prescribing and dispensing patterns for medications. 3) Each client's care team, how healthcare services are coAPSA-ASCEPT-poster-abstracts-51217
ordinated and his/her understanding of their regular medications.Methods. Participants were recruited from three metropolitan community pharmacies in APSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 g dispensing histories of those 65 years and over. Data analysis was conducted using descriptive statistics.Results. Forty-five face-to-face interviews were conducted. Participants were taking 7.45 medicines on average with 76% using five or more regular medicines. Two hundred and twenty-three dispe APSA-ASCEPT-poster-abstracts-51217 nsing histories were collected. The average number of medicines taken by each participant was 8.27 with 86% of participants taking five or more regulaAPSA-ASCEPT-poster-abstracts-51217
r medicines.Discussion. A significant proportion of older Australians living in community dwellings were exposed to polypharmacy. Themes including lacAPSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 n about medicines for patients were highlighted 11APSA ASCEPT 2017 Joint Soent.fic Meeting - Book of poster abstractsPagel 1117APSA-ASCEPT JOINT SCIENTIFIC MEETING402Use of medicines with sedative or anticholinergic properties and medicine-induced deterioration in older people: an intermediary pathw APSA-ASCEPT-poster-abstracts-51217 ay to frailtyRenly Um1, Lisa M. Kalisch Ellett1, Imaina $. Widagdo1, Nicole L. Pratt1, Elizabeth E. Roughead1. Quality Use of Medicines and Pharmacy RAPSA-ASCEPT-poster-abstracts-51217
esearch Centre, Sansom Institute for Health Research, University of South Australia, Adelaide, SA, Australia.Introduction. Medicines With sedative or APSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 ed.Aims. To study the association between use of medicines with sedative or anticholinergic properties and I) medicine-induced deterioration (physical function, cognition or appetite), and ii) frailty.Methods. The study population consisted of persons aged >65 years (n=2087) enrolled in the Australi APSA-ASCEPT-poster-abstracts-51217 an Longitudinal Study of Ageing (ALSA). Physical function was measured using hand grip strength, walking speed, chair stands, activities of daily liviAPSA-ASCEPT-poster-abstracts-51217
ng (ADL) and instrumental activities of daily living (IADL). Cognitive function was measured using the Mini Mental State Examination (MMSE), while appAPSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 ty was measured using the frailty index.Results. Almost half of the population were using medicines with sedative or anticholinergic properties (n=954, 45.7%). After adjusting for confounders, use of medicines with sedative or anticholinergic properties was associated with slower walking speed (pcO. APSA-ASCEPT-poster-abstracts-51217 OOl), poorer performance on chair stands (p=0.017) and poorer IADL score (p<0.001). There was no Significant association between medicine use and cognAPSA-ASCEPT-poster-abstracts-51217
itive function. Use of medicines with anticholinergic properties was associated with poorer appetite (p<0.001). Participants who used medicines with sAPSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 ys by which use of medicines with sedative or anticholinergic properties contribute to frailty, either directly or via an intermediary pathway. Preventing medicine-induced deterioration is important to reduce risk of frailty and subsequent adverse events such as falls and fractures.403'Real-world' h APSA-ASCEPT-poster-abstracts-51217 aemorrhagic rates for antithrombotics using a self-conUolled case series designPrasad $ Nishtala, PhD1 and Te-yuan Chyou, PhD1, School of Pharmacy, UnAPSA-ASCEPT-poster-abstracts-51217
iversity of Otago, Dunedin, Otago, New Zealand,Introduction: Population level evidence for the safety of using antithrombotics in older people within APSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 ntiplatelets, anticoagulants either as monotherapy, dual antiplatelet therapy (DAPT) or triple therapy (TT) under the context of confounding due to multi-morbidity. Methods: Self-controlled case-series (sees) design and conditional Poisson regression (CPR) were used In this investigation. We identif APSA-ASCEPT-poster-abstracts-51217 ied 3378 individuals aged 65 and above, who had been diagnosed for the first time with Gi-bleeding event, between 01/01/2005 and 31/12/2014. sees desiAPSA-ASCEPT-poster-abstracts-51217
gn controls for time-invariant confounding variables was used to estimate the increased risk of Gl-bleeding due to DAPT, TT or the monotherapies, as iAPSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 the cohort, 78% (n = 2624) hadtheir first-time Gi-bleeding with antithrombotic exposures. Antiplatelet monotherapy (adjusted IRR = 3.75, 95% Cl = [3.03, 4.63)) and DAPT (adjusted IRR = 4.19, 95% Cl = [1.78, 9.86]) were associated with a higher Gl-bleeding risk compared to anticoagulant and aspirin APSA-ASCEPT-poster-abstracts-51217 monotherapies. The risk of GI-bleeding was highest with TT use compared with anticoagulant and antiplatelet dual therapy use and the monotherapies (adAPSA-ASCEPT-poster-abstracts-51217
justed IRR = 10.02, 95% Cl = [5.51, 18.21)).Conclusions: The Gl bleeding risk was higher in individuals using TT compared to anticoagulant and antiplaAPSA-ASCEPT JOINT SCIENTIFIC MEETING400Trends In anticoagulant use among people with dementia in AustraliaJenni llomãki1, Amy Page1, Maarit Jaana Korh APSA-ASCEPT-poster-abstracts-51217 2017 Joint Scientific Meetina - Book of postw abstractsPage 2 1117APSA-ASCEPT JOINT SCIENTIFIC MEETING404Health professionals' and researchers' opinions on conducting clinical deprescribing trialsAlexander J Clough1-2, Sarah N Hilmer2, Lisa Kouladjian-O'Donnell2, Sharon L Naismith1, Danijela Gnjidi APSA-ASCEPT-poster-abstracts-51217 c12-3. Fac of Pharmacy, Univ of Sydney1, Camperdown, NSW, Australia: Kolling Inst. Royal North Shore Hospital and Univ of Sydney1, St Leonards, NSW, AAPSA-ASCEPT-poster-abstracts-51217
ustralia; Brain & Mind Research Inst, Univ of Sydney’, Camperdown, NSW, AustraliaIntroduction. Clinical deprescribing trials can be conducted to produGọi ngay
Chat zalo
Facebook